Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Verbascoside

Catalog No: tcsc2624

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
61276-17-3

Formula:
$C_{29}H_{36}O_{15}$

Pathway:
TGF-beta/Smad;Epigenetics

Target:
PKC;PKC

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 6.3 mg/mL (10.09 mM)

Alternative Names:
Acteoside;Kusaginin;TJC160

Observed Molecular Weight:
624.59

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Verbascoside is isolated from *Lantana camara*, acts as an ATP-competitive inhibitor of **PKC**, with an **IC_{50}** of 25 μM, and has antitumor, anti-inflammatory and antineuropathic pain activity.

IC50 & Target: IC50: 25 μM (PKC)[1]

In Vitro: Verbascoside acts as an ATP-competitive inhibitor of PKC, with an IC_{50} of 25 μM. Verbascoside shows K_is of 22 and 28 μM with respect to ATP and histone, respectively. Verbascoside has potent antitumor activity against L-1210 cells, with an IC_{50} of 13 μM [1]. Verbascoside (5, 10 μM) suppresses 2,4-dinitrochlorobenzene (DNCB)-induced T cell costimulatory factors CD86 and CD54, proinflammatory cytokines, and NFκB pathway activation in THP-1 cells[2].

In Vivo: Verbascoside (1%) reduces the overall scratching behavior incidence as well as the severity of the skin lesions in 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD) mice model. Verbascoside also blocks DNCB-induced expression of proinflammatory cytokine TNF-α, IL-6, and IL-4 mRNA in skin lesions[2]. Verbascoside (50, 100 mg/kg, i.p.) does not modify chronic constriction injury (CCI)-induced cold allodynia. Verbascoside (200 mg/kg, i.p.) decreases hyper-sensitivity to cold stimulus, acetone, on day 3 in rats. Verbascoside also significantly reduces behavioral changes associated with neuropathy. Moreover, Verbascoside decreases Bax and increases Bcl-2 on day 3[3].